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Children’s Hospital of Fudan University, Shanghai, ChinaAbstractA new quadrivalent inﬂuenza vaccine has been available for inﬂuenza B, which can pose a signiﬁcant global health burden. Shanghai has the highest
GDP and largest metropolitan population in China. To understand the impact of inﬂuenza B in Shanghai in terms of age-related incidence and
relative prevalence compared with other subtypes, we conducted this retrospective epidemiological study of inﬂuenza B in the 2009–2014
seasons. A total of 71 354 outpatients with inﬂuenza-like illness were included, and both lineages of inﬂuenza B and subtypes of inﬂuenza A
were identiﬁed using real-time RT-PCR. The antigenic characteristics of inﬂuenza B isolates were analysed by sequencing and reciprocal
haemagglutinin inhibition assay. On average, 33.45% of inﬂuenza strains were inﬂuenza B, and 40.20% of strains isolated from children were
inﬂuenza B. The incidence of inﬂuenza B was highest (12.52 per 100 people with inﬂuenza-like illness) in children ages 6–17 years and usually
peaked in this age group at the early stage of an inﬂuenza B epidemic. Overall, both matched and mismatched inﬂuenza B strains co-circulated
in Shanghai annually, and 44.57% of the circulating inﬂuenza B belonged to the opposite lineage of the vaccine strains. We concluded that
inﬂuenza B has caused a substantial impact in Shanghai and that school-aged children play a key role in the transmission of inﬂuenza B. Hence,
it may be beneﬁcial to prioritize inﬂuenza vaccination for school-aged children to mitigate the outbreaks of inﬂuenza B.
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
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this article.IntroductionInﬂuenza B virus has led to a substantial morbidity and mortality
burden in mainland China in recent seasons. More than half of allMicrobiol Infect 2015; 21: 694–700
nical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
is is an open access article under the CC BY-NC-ND license (http://creativecommons.org/lice
p://dx.doi.org/10.1016/j.cmi.2015.03.009inﬂuenza-associated mortality between 2003 and 2008 in
temperate and subtropical Chinese cities was associated with
inﬂuenza B [1,2]. These viruses represent two lineages that have
co-circulated globally since 2001 [3,4]. Vaccination is the primary
measure to prevent inﬂuenza and reduce its impact, and vaccine
efﬁcacy is determined mainly by the degree of haemagglutinin
(HA) antigen matching between the vaccine and circulating
strains [5]. For inﬂuenza B viruses, antigenic relatedness is
further complicated by the existence of the two distinct lineages.
Recent surveillance data from the United States and Europe
between 2001 and 2011 showed that 46–58% of circulating
inﬂuenza B lineages were mismatched to the vaccine strain [6,7].
Although Shanghai has the highest GDP in China, the coverage
rate of inﬂuenza vaccination is low, largely because of the limited
public knowledge about inﬂuenza and vaccine-related beneﬁts
and the annual inﬂuenza vaccination having no governmentEuropean Society of Clinical Microbiology and Infectious Diseases
nses/by-nc-nd/4.0/)
CMI Zhao et al. Epidemiology of inﬂuenza B 695reimbursement [8]. Currently, a quadrivalent inﬂuenza vaccine
containing both inﬂuenza B lineages could improve protection
against inﬂuenza B and reduce the burden and outcomes of sea-
sonal inﬂuenza illness [9]. However, adoption of this vaccine ap-
pears not to be feasible at present for budgetary reasons.
Data regarding the epidemiology of inﬂuenza B in mainland
China are sparse. The aim of this retrospective surveillance
study was therefore to assess the impact of inﬂuenza B in age
groups of outpatients with inﬂuenza-like illness (ILI) in terms of
incidence and relative prevalence compared with other sub-
types, analyse the mismatch ratio between the circulating and
vaccine strains, and trace the genetic and antigenic changes in
inﬂuenza B viruses during the 2009–2014 seasons in Shanghai.Materials and methodsEthics statement
The study was reviewed and approved by the Shanghai Municipal
Centre for Disease Control and Prevention Ethical Review
Committee. All participants were informed about the study by the
medical staff before sample collection, and the participants who
consented provided their signature on the sample information
sheet. If the participants were children, their parents, grandpar-
ents or guardians were informed and provided the signed consent.
Sample collection
The enrolment criteria for surveillance cases included: (a)
outpatients seeking medical care at the designated sentinel
hospitals for ILI, deﬁned as an acute respiratory infection with
measured body temperature 38°C and cough or sore throat;
(b) onset of ILI clinical symptoms within 3 days; and (c) no
treatment with anti-virals. Nasopharyngeal swabs or throat
swabs were taken from surveillance cases throughout the week,
and sentinel hospitals collected 10–20 specimens every week,
according to the protocol of the Chinese Inﬂuenza Centre
(CNIC, Inﬂuenza Surveillance Program for Mainland China,
2010: http://www.cnic.org.cn/chn/down/showdown.php?
downid=642). Specimens were kept in 3 mL of virus trans-
port medium at 4°C and sent to the corresponding district
network laboratories within 24 h. Meanwhile, participating
physicians completed sample information sheets, including the
demographic information, chief complaint, and date of ILI onset
and hospital visit. The related information about the patients
was input into the Chinese inﬂuenza Surveillance Net.
Laboratory detection of inﬂuenza viruses and inﬂuenza
B lineage
Network laboratories carried out nucleic acid detection and
virus isolation within 48 h of receiving the specimens. ViralClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an open access artinucleic acid was extracted and detection of inﬂuenza A and B
viruses and identiﬁcation of inﬂuenza B lineages were per-
formed by real-time RT-PCR assays according to the standard
protocols of WHO (WHO, Manual for the laboratory diagnosis
and virological surveillance of inﬂuenza. Available at: http://
www.who.int/inﬂuenza/gisrs_laboratory/manual_diagnosis_
surveillance_inﬂuenza/en/).
Antigenic analysis
Samples positive for inﬂuenza B viruses, as conﬁrmed by real-
time RT-PCR, were isolated by inoculation into Madin–Darby
canine kidney cells. All successfully cultured inﬂuenza virus
isolates were then submitted to the Chinese Inﬂuenza Centre
for further reciprocal HA inhibition characterization, which was
performed using post-infection ferret serum against WHO-
recommended strains and guinea pig erythrocytes. The iso-
lates were identiﬁed as low-reaction strains to the prototype
reference strains when a reduction of at least eight-fold was
detected in the HA inhibition titres, which is considered a signal
of potential antigenic drift.
A total of 108 isolates, including 43 B/Victoria and 65 B/
Yamagata, were randomly selected for sequencing using an ABI
3730xl automatic DNA analyser (Life Technologies, Carlsbad,
CA). Genome sequences were deposited in the Global Initiative
on Sharing Avian Inﬂuenza Data (GISAID) (http://www.
platform.gisaid.org). The sequenced strain names and acces-
sion numbers are listed in the Supporting information
(Table S1). For phylogenetic analysis, HA and neuraminidase
nucleotide sequences of the WHO-recommended inﬂuenza B
vaccine strains for use in the 2009–2014 northern hemisphere
seasons were downloaded from GISAID. Sequence alignments
were performed with MEGALIGN in the LAGERGENE 7.01 soft
package. A phylogenetic tree was generated using MEGA
(version 5.10) software applying the neighbour-joining method
with 1000 bootstrap replicates.
Data management and statistical analysis
Statistical analysis and data management were performed using
SPSS (Version 11.5; SPSS Inc., Chicago, IL, USA). The graphs
were drawn using GRAPHPAD PRISM software (Version 5.01;
GraphPad, La Jolla, CA, USA).ResultsActivity of inﬂuenza B
A total of 71 354 outpatients with ILI were included in the
surveillance cases over the ﬁve seasons. Of the 71 354 samples,
a total of 6688 (9.37%) were positive for inﬂuenza B viruses;
7531 (10.55%) were positive for A/H3N2 viruses; 45 (0.06%)of European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 694–700
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
696 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIwere positive for seasonal A/H1N1 viruses; 5755 (8.07%) were
positive for 2009 pandemic inﬂuenza A/H1N1 viruses; one
(0.001%) was positive for avian inﬂuenza A/H7N9 virus, iden-
tiﬁed in early April 2013; and 14 (0.02%) were co-infected with
two inﬂuenza viruses. On average, 33.45% of inﬂuenza cases
during the ﬁve seasons were caused by inﬂuenza B.
Prevalence of laboratory-conﬁrmed inﬂuenza B in
different age groups
The age-speciﬁc frequency of inﬂuenza B in ILI cases for age
group <2 years, 2–5 years, 6–17 years, 18–64 years, and 65
years old were 3.20% (range 0–36.36%), 6.63% (range
0–59.44%), 12.52% (range 0–62.35%), 9.53% (range 0–64.36%)
and 8.41% (0–56.90%), respectively, by real-time RT-PCR
assay. The prevalence of inﬂuenza B was signiﬁcantly higher in
children ages 6–17 years than in other age groups (p < 0.001).
Compared with inﬂuenza A/H3N2 and A/H1N1, the prevalence
of inﬂuenza B was also signiﬁcantly higher in the 6–17-year age
group (p < 0.001; chi-square test). The proportion of illnesses
caused by inﬂuenza B relative to inﬂuenza A subtypes was
highest (40.2%) for children ages 6–17 years (Table 1).
Compared with the other age groups, the frequency of inﬂu-
enza B was highest in those age 6–17 years during the early
stage of the epidemic and throughout the season (Fig. 1).
Matching ratio between circulating and vaccine B
strains
During 2009, 2010, 2011 and 2012, the B/Victoria lineage of
viruses predominated over the B/Yamagata lineage of viruses;
2.74–48.28% of the circulating inﬂuenza B viruses belonged to
the B/Yamagata lineage, the opposite lineage to the 2009–2012
northern hemisphere inﬂuenza vaccine. Remarkably, in 2012,
the percentages of matched and mismatched inﬂuenza B viruses
in circulation were greatly disproportionate (2.74% versus
97.26%, respectively). After the largest outbreak of inﬂuenza B
caused by the B/Victoria lineage of viruses in the 2012 season,TABLE 1. Frequency and proportion of age-speciﬁc laboratory-con
Age group
Total no. of
enrolled ILI
cases
Number (frequency) of inﬂuenza
cases by age and virus
Age gInﬂuenza B
Inﬂuenza
A/H1N1
Inﬂuenza
A/H3N2
<2 years 3191 102 (3.20%) 91 (2.85%) 157 (4.92%) <2 yea
2–5 years 8207 544 (6.63%) 416 (5.07%) 587 (7.15%) 2–5 ye
6–17 years 12 544 1571(12.52%)a 1102 (8.79%) 1237 (9.86%) 6–17 y
18–64 years 43 062 4105 (9.53%) 4018 (9.33%) 4855 (11.27%) 18–64
65 years 4350 366 (8.41%) 123 (2.83%) 695 (15.98%) 65 ye
All groups 71 354 6688 (9.37%) 5755 (8.07%) 7531 (10.55%) all grou
aThe percentage of real-time RT-PCR-positive inﬂuenza B specimens in the 6–17 years old gr
RT-PCR-positive inﬂuenza B specimens is higher than pandemic inﬂuenza A/H1N1, A/H3N2 i
SPSS software (Version 11.5).
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became the predominant circulating strain. Inﬂuenza B/Yama-
gata activity was at an extremely high level in 2013 and 2014
when 97.51% and 98.46% of circulating inﬂuenza B viruses
belonged to the same lineage (Fig. 2). On average, 44.57% of
circulating inﬂuenza B lineages during the consecutive seasons
was of a lineage that differed antigenically from the vaccine
strains.
Antigenic characterization
According to the reciprocal HA inhibition assay, percentages of
low-reaction strains of B/Victoria and B/Yamagata compared
with the vaccine strains were as high as 64.86% and 58.28% in
2009 and 2011, respectively. Among 1229 detected B/Victoria
strains, the percentages of low-reaction strains in 2010, 2011
and 2012 were 0%, 13.19% and 24.69%, respectively; however,
these values returned to 0% in 2013 and 2014 when the B/
Yamagata lineage was predominant. Similarly, the percentage of
low-reaction B/Yamagata strains also increased year by year
when the new vaccine changed the inﬂuenza B component. In
contrast, the low-reaction strains of B/Yamagata were 14 of 55
(25.45%) in 2014, the ﬁrst year when a vaccine strain containing
a B/Massachusetts/2/2012 component was used (Table 2).
The phylogenic trees constructed from sequencing the genes
of 65 B/Yamagata-lineage strains suggested a reassortment
within the two lineages. Twenty-two (33.85%) B/Yamagata vi-
ruses, containing a Yamagata lineage HA gene and Victoria
lineage NA gene, formed a new genetic subclade. It is worth
noting that 91.91% (20/22) of the reassortants were isolated
from 2014 cases (Fig. 3).DiscussionShanghai is the largest and most populated city in mainland
China, with a resident population of over 24 million and aﬁrmed inﬂuenza cases by virus type and subtypes
roup
Total no. of
laboratory
-conﬁrmed cases
No. (proportion) of inﬂuenza cases by
age and virus
Inﬂuenza B
Inﬂuenza
A/H1N1
Inﬂuenza
A/H3N2
rs 350 102 (29.14%) 91 (26.00%) 157 (44.86%)
ars 1547 544 (35.16%) 416 (26.89%) 587 (37.94%)
ears 3910 1571 (40.18%) 1102 (28.18%) 1237 (31.64%)
years 12 978 4105 (31.63%) 4018 (30.96%) 4855 (37.41%)
ars 1184 366 (30.92%) 123 (10.39%) 695 (58.70%)
ps 19 974 6688 (33.48%) 5755 (28.81%) 7531 (37.70%)
oup is signiﬁcantly higher than other age groups. Similarly, the percentage of real-time
n 6–17 years old group. The statistical analysis was performed by chi-square test using
European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 694–700
nses/by-nc-nd/4.0/)
FIG. 1. The percentage of real-time
RT-PCR-positive inﬂuenza B speci-
mens by age group and month, August
2009 to July 2014 sentinel surveillance
period. Left y-axis represents the real-
time RT-PCR-positive percentage of
inﬂuenza B viruses in outpatients with
inﬂuenza-like illness (ILI) every month
in this age group. The x-axis shows
study period, from August 2009 to
July 2014 by month. The period from
August to July of the next year is
deﬁned as one inﬂuenza season. The
group <2 years old is shown by a red
line; the 2–5 years group is shown by
a purple line; the 6–17 years group is
shown by a yellow line; the 18–64
years group is shown by a green line
and the 65 years group is shown by
a black line. (a–c) show three inﬂu-
enza B epidemics in the period stud-
ied. The enlarged graphs below show
that the inﬂuenza B-positive percent-
age peaked earlier (a, c) or simulta-
neous (b, d) in the 6–17-year age
group than in other age groups.
CMI Zhao et al. Epidemiology of inﬂuenza B 697temperate climate. The inﬂuenza surveillance data from
Shanghai during the 2009–2014 seasons demonstrated a sig-
niﬁcant impact of inﬂuenza B on public health, similar to that of
inﬂuenza A/H3N2 and pandemic A/H1N1. This ﬁnding is in
agreement with those of other studies [10–12]. In addition, the
seasonal outbreaks of inﬂuenza B commonly started among
school-aged children aged 6–17 years and then spread to the
general population. In keeping with this result, a recent study in
central China evaluating severe acute respiratory infections
from 2010 to 2012 showed that inﬂuenza B-associated hospi-
talization rates were highest among children [13].
Our surveillance study identiﬁed a higher incidence rate
and earlier peak of inﬂuenza B occurring among children ages
6–17 years than among younger and older age groups. In
addition, the prevalence of ILIs caused by inﬂuenza B relative
to inﬂuenza A was highest for children in this age group. OurClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an open access artiﬁndings are consistent with those of a previous study [14].
Given these results, targeted immunization among school-
aged children might be effective in reducing the spread of
inﬂuenza B to the general population during epidemic sea-
sons, which is a conclusion in line with other studies [13,15].
In addition, children shed greater amounts of virus for a
longer time than adults [16], which means that they
frequently infect those at home and consequently exacerbate
the inﬂuenza-related economic burden on the family [17].
Vaccination of school-aged children has been suggested to
provide both direct protection for the vaccinated population
and indirect protection for unvaccinated age groups within
the population during inter-pandemic as well as pandemic
periods [18,19].
The vaccine now used in Shanghai is a trivalent inﬂuenza
vaccine, which includes only one lineage of inﬂuenza B [8,20]. Inof European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 694–700
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
FIG. 2. Distribution of inﬂuenza B lineage in
Shanghai in the past six seasons. Black boxes
represent Yamagata lineage; white boxes
represent Victoria lineage. Asterisks indi-
cate the WHO-recommended inﬂuenza B
vaccine strain of that year.
698 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIthis study, we found that lineages of inﬂuenza B viruses that
were matched and mismatched to the vaccine strains co-
circulated in each season at varying levels, which could
reduce the efﬁcacy of trivalent inﬂuenza vaccine. Moreover,
mismatched inﬂuenza B viruses were observed in some sea-
sons, although in a minority of them. In the 2012 season, for
example, almost all of the circulating inﬂuenza B viruses were
not antigenically matched to the vaccine strain. In addition, co-
circulation of the two lineages could result in a different pattern
of evolution of inﬂuenza B virus; our phylogenetic analysis
revealed reassortment between the B/Victoria and B/Yamagata
lineages. Antigenic characterization by reciprocal HA inhibition
assay showed that more than one-quarter of B/Yamagata iso-
lates belonged to the low-reaction strains of the WHO-
recommended vaccine in 2014, the ﬁrst year in which theTABLE 2. Result of reciprocal haemagglutination inhibition
assay
Lineage Year Reference seruma
No. of
inﬂuenza
B strains
for test
No. of low
reaction
strains %
B/Victoria 2009 B/Malaysia/2506/2004 37 24 64.86
2010 B/Brisbane/60/2008 142 0 0
2011 B/Brisbane/60/2008 470 62 13.19
2012 B/Brisbane/60/2008 571 141 24.69
2013 B/Brisbane/60/2008 6 0 0
2014 B/Brisbane/60/2008 3 0 0
B/Yamagata 2009 B/Florida/4/2006 16 3 18.75
2010 B/Florida/4/2006 65 28 43.08
2011 B/Florida/4/2006 151 88 58.28
2012 B/Wisconsin/01/2010 27 0 0
2013 B/Wisconsin/01/2010 15 0 0
2014 B/Massachusetts/2/2012 55 14 25.45
aThe post-infection ferret serum against the WHO-recommended vaccine strains.
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used. The genetic and antigenic characteristics of circulating
inﬂuenza B highlight a need for using a quadrivalent inﬂuenza
vaccine to provide broad protection against both lineages of
inﬂuenza B and offer beneﬁts for vaccine recipients and public
health.
Unfortunately, the average annual coverage rate of the
trivalent inﬂuenza vaccine in Shanghai has been quite low: about
16 doses per 1000 people during the six past seasons (un-
published data from Shanghai Centre for Disease Control and
Prevention). In contrast, the rate of inﬂuenza vaccine inocula-
tion in Beijing is the highest in China, with the city providing
free vaccination for citizens over 60 years and subsidizing half of
the cost of the vaccine for primary and high school children
since 2007 [8]. Although general subsidies currently might not
be economically feasible in Shanghai, it might be feasible for the
government to choose a target group for whom to subsidize
the cost of the vaccine. Given the higher disease burden of
inﬂuenza B among school-aged children and their key role in
transmission, priority immunization of this age group might be
the most practical way to improve the effectiveness of inﬂuenza
vaccination and reduce the spread of inﬂuenza B to the com-
munity population.
This study ﬁlls an important gap in the epidemiology of
inﬂuenza B in mainland China and supports data previously
published from the USA and European countries [21,22]. The
results arising from this surveillance study offer a strong
epidemiological rationale for using quadrivalent inﬂuenza vac-
cine in Shanghai, especially in school-age children, and for
considering subsidizing inﬂuenza vaccination in at least this
subset of the population. A cost-effectiveness analysis is neededEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 694–700
nses/by-nc-nd/4.0/)
FIG. 3. Phylogenic tree of inﬂuenza B/Yamagata virus haemagglutinin (HA) region and neuraminidase (NA) sequences in Shanghai. Multiple alignments
were constructed by using the MUSCLE algorithm (a multiple alignment method with reduced time and space complexity) of MEGA software version
5.10. Phylogenic trees were constructed by using the neighbour-joining method with bootstrap analyses of 1000 replications. Bootstrap values >60 are
shown in the nodes. Sequences of the WHO-recommended inﬂuenza B vaccine strains are shown in red; Sequences of reassortment inﬂuenza B virus
that contained Yamagata lineage HA and Victoria lineage NA are shown in blue. These reassortants formed a new genetic subclade. The scale bar
indicates substitutions per site.
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700 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIbefore recommending quadrivalent inﬂuenza vaccine as the
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